Original news and analysis on international IP policy
With implementation of the World Health Organization strategy on intellectual property and innovation beginning in earnest, international experts this week debated how human rights could be infused into global health strategies - including the possibility of new international agreements on research and development - and whether WHO is up to the task.
An international coalition of consumer groups has issued a resolution calling into question global enforcement policy and offering core principles for policymakers to consider in setting new enforcement standards.
Major public health funders have alighted upon an industry-favoured approach of guaranteeing certain prices to industry to make vaccines available to least-developed country markets.
Draft rules on intellectual property rights in publicly financed research are stirring significant debate in South Africa between those who say the rules may stifle innovation, breach WHO commitments and be unconstitutional, and others who say concerns are overblown and the measures are needed to boost the country's economy.
Counterfeit medicines were left off this year’s truncated World Health Assembly agenda but still managed to have an impact. The contentious, intellectual property-related issue arose during a discussion on the World Health Organization’s future plans, as several nations objected to a budget line referencing a programme to combat counterfeit drugs.
Responsibility to take forward a still in-progress framework to cope with global influenza pandemics is now in the hands of the World Health Organization Director General Margaret Chan, member states agreed in a meeting Thursday. This was approved by the full World Health Assembly on Friday.
Applause broke out at the annual World Health Assembly Friday as agreement was reached at the end of a five-year process to devise a plan for boosting research and development on and access to drugs needed by developing countries. Now with the full assembly's approval, the focus will turn to implementation and as-yet unclear ways to pay for it.
Some five years after setting a mandate to address barriers faced by poor countries in accessing needed medicines, World Health Organization members are near agreement on a strategy and plan of action. But a key question remains on WHO involvement in a possible treaty on biomedical research and development for diseases disproportionately affecting developing nations, and the WHO secretariat is facing accusations that the process has not been amply inclusive.
As the world looks to the World Health Assembly for a plan of action in case of pandemic, delegates are negotiating remaining parts of a framework for pandemic influenza preparedness, and an associated model agreement for the movement of virus and vaccine-related materials.
A procedural agreement might come as early as Tuesday afternoon, but it remains to be seen whether agreement can be reached on how to handle uncompleted work.
A series of meetings intended to set out a global framework for dealing with a potential pandemic completed its last session Saturday night with progress made but several essential issues still uncompleted.
The annual World Health Assembly kicks off Monday with key issues of intellectual property and public health on the agenda, but the plan to end the assembly early this year in the face of the pandemic influenza crisis has trimmed talks on counterfeit medicines from the meeting, according to official sources.
The United Nations human rights framework is being brought to bear on intellectual property law, in the hopes that the weight of expert voices in human rights can lead IP regimes toward a better balance between the needs of industry and the needs of public policy.